Back to News
Market Impact: 0.15
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Vaxart CEO Steve Lo highlighted the company’s oral vaccine platform at an H.C. Wainwright conference, including a government-funded COVID-19 study and development opportunities in norovirus and influenza. The presentation signals continued pipeline development but disclosed no new clinical results, financial figures, regulatory milestones, or commercial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
More News
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Why Dave & Buster's Stock Tumbled Today
- Flotek Industries director Matthew Wilks adds $34.3m to holdings
- Trump calls AI fears a 'hoax', Treasury yields surge, Moynihan's warning and more in Morning Squawk
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix